Triptans News and Research

RSS
Cluster headaches: searching for effective therapies

Cluster headaches: searching for effective therapies

Study may open door to developing cure for headache during flight

Study may open door to developing cure for headache during flight

RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT™ for migraines with Grupo JUSTE in Spain and additional potential territories

RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT™ for migraines with Grupo JUSTE in Spain and additional potential territories

Worsening migraine no reason to halt dihydroergotamine infusion

Worsening migraine no reason to halt dihydroergotamine infusion

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

CGRP monoclonal antibodies show promise in treating migraine

CGRP monoclonal antibodies show promise in treating migraine

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

AHS provides updated assessment of treatments for acute migraine

AHS provides updated assessment of treatments for acute migraine

Improving headache treatment could reduce health care spending, new study suggests

Improving headache treatment could reduce health care spending, new study suggests

Study shows why certain drugs that interact with serotonin receptors have harmful effects

Study shows why certain drugs that interact with serotonin receptors have harmful effects

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

Migraine is a neurological, not vascular, disorder

Migraine is a neurological, not vascular, disorder

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro in Germany and the UK

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro in Germany and the UK

Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark

Denmark grants marketing authorization for SUMAVEL DosePro Needle-Free Delivery System

Denmark grants marketing authorization for SUMAVEL DosePro Needle-Free Delivery System

NeurAxon’s NXN-188 compound effective for acute migraine treatment

NeurAxon’s NXN-188 compound effective for acute migraine treatment

MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

Sales of Merck's telcagepant and CoLucid's lasmiditan in world's major markets to reach $1.3 billion in 2019

Sales of Merck's telcagepant and CoLucid's lasmiditan in world's major markets to reach $1.3 billion in 2019

High dose aspirin effective for treatment of severe headache and migraine

High dose aspirin effective for treatment of severe headache and migraine